Cytosorbents Corp
For the period ended Nov 13, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 13, 2025 · Filed Nov 13, 2025
Use the contents to explore the available documents and sections.
CTSO$4.80+4.3%Stored close · as of Nov 6, 2026
Contents
EX-99 · (in thousands, except share data)
(in thousands, except share data)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $7,536 | $3,280 |
| Restricted cash, current | — | 5,000 |
| Accounts receivable, net of allowances of $134 and $158 as of September 30, 2025 and December 31, 2024, respectively | 7,427 | 7,320 |
| Inventories | 4,002 | 2,733 |
| Prepaid expenses and other current assets | 2,348 | 3,271 |
| Total current assets | 21,313 | 21,604 |
| Property and equipment - net | 8,193 | 9,002 |
| Restricted cash | 1,522 | 1,484 |
| Right-of-use asset | 11,075 | 11,511 |
| Other assets | 3,647 | 3,771 |
| Total assets | $45,750 | $47,372 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $3,035 | $3,340 |
| Accrued expenses and other current liabilities | 6,559 | 6,032 |
| Lease liability – current portion | 518 | 453 |
| Total current liabilities | 10,112 | 9,825 |
| Lease liability, net of current portion | 12,051 | 12,444 |
| Long-term debt | 14,567 | 13,996 |
| Total liabilities | 36,730 | 36,265 |
| Commitments and Contingencies | ||
| Stockholders’ equity | ||
| Preferred Stock, par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common Stock, par value $0.001, 100,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 62,794,305 and 54,830,146 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 63 | 55 |
| Additional paid-in capital | 319,511 | 310,809 |
| Accumulated other comprehensive income (loss) | (3,844) | 4,252 |
| Accumulated deficit | (306,710) | (304,009) |
| Total stockholders’ equity | 9,020 | 11,107 |
| Total liabilities and stockholders’ equity | $45,750 | $47,372 |
See accompanying notes to condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.